OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice
Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research (2022) Vol. 52, Iss. 9, pp. 773-783
Open Access | Times Cited: 56
Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research (2022) Vol. 52, Iss. 9, pp. 773-783
Open Access | Times Cited: 56
Showing 1-25 of 56 citing articles:
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Matthias Pinter, Bernhard Scheiner, David J. Pinato
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 8, pp. 760-770
Closed Access | Times Cited: 57
Matthias Pinter, Bernhard Scheiner, David J. Pinato
The Lancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 8, pp. 760-770
Closed Access | Times Cited: 57
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
Fabio Piscaglia, Gianluca Masi, Erika Martinelli, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104110-104110
Closed Access | Times Cited: 3
Fabio Piscaglia, Gianluca Masi, Erika Martinelli, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104110-104110
Closed Access | Times Cited: 3
Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib
Takeshi Terashima, Hidenori Kido, Noboru Takata, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 278-278
Open Access | Times Cited: 2
Takeshi Terashima, Hidenori Kido, Noboru Takata, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 278-278
Open Access | Times Cited: 2
Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience
Anand V. Kulkarni, Vamsi Krishna, Karan Kumar, et al.
Journal of Clinical and Experimental Hepatology (2023) Vol. 13, Iss. 4, pp. 618-623
Open Access | Times Cited: 31
Anand V. Kulkarni, Vamsi Krishna, Karan Kumar, et al.
Journal of Clinical and Experimental Hepatology (2023) Vol. 13, Iss. 4, pp. 618-623
Open Access | Times Cited: 31
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Anand V. Kulkarni, Harsh Vardhan Tevethia, Karan Kumar, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102179-102179
Open Access | Times Cited: 26
Anand V. Kulkarni, Harsh Vardhan Tevethia, Karan Kumar, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102179-102179
Open Access | Times Cited: 26
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology (2023) Vol. 101, Iss. 10, pp. 624-633
Closed Access | Times Cited: 24
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology (2023) Vol. 101, Iss. 10, pp. 624-633
Closed Access | Times Cited: 24
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
Machiko Kai, Hayato Hikita, Maesaka Kazuki, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0294590-e0294590
Open Access | Times Cited: 9
Machiko Kai, Hayato Hikita, Maesaka Kazuki, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0294590-e0294590
Open Access | Times Cited: 9
Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
Xiaoqiang Gao, Rui Zhao, Huaxing Ma, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 18
Xiaoqiang Gao, Rui Zhao, Huaxing Ma, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 18
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
George Lau, Shuntaro Obi, Jian Zhou, et al.
Hepatology International (2024) Vol. 18, Iss. 6, pp. 1661-1683
Open Access | Times Cited: 7
George Lau, Shuntaro Obi, Jian Zhou, et al.
Hepatology International (2024) Vol. 18, Iss. 6, pp. 1661-1683
Open Access | Times Cited: 7
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, et al.
Hepatology Research (2022) Vol. 53, Iss. 2, pp. 104-115
Closed Access | Times Cited: 24
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, et al.
Hepatology Research (2022) Vol. 53, Iss. 2, pp. 104-115
Closed Access | Times Cited: 24
FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
Iason Psilopatis, Christos Damaskos, Anna Garmpi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2685-2685
Open Access | Times Cited: 16
Iason Psilopatis, Christos Damaskos, Anna Garmpi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2685-2685
Open Access | Times Cited: 16
Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
Jaekyung Cheon, Hyeyeong Kim, Han Sang Kim, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 13
Jaekyung Cheon, Hyeyeong Kim, Han Sang Kim, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 13
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 242-251
Open Access | Times Cited: 12
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 242-251
Open Access | Times Cited: 12
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
Shintaro Takaki, Masayuki Kurosaki, Nami Mori, et al.
Investigational New Drugs (2023) Vol. 41, Iss. 2, pp. 340-349
Closed Access | Times Cited: 12
Shintaro Takaki, Masayuki Kurosaki, Nami Mori, et al.
Investigational New Drugs (2023) Vol. 41, Iss. 2, pp. 340-349
Closed Access | Times Cited: 12
Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
Ji Won Han, Jeong Won Jang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11799-11799
Open Access | Times Cited: 12
Ji Won Han, Jeong Won Jang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11799-11799
Open Access | Times Cited: 12
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
PLoS ONE (2023) Vol. 18, Iss. 2, pp. e0281459-e0281459
Open Access | Times Cited: 11
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
PLoS ONE (2023) Vol. 18, Iss. 2, pp. e0281459-e0281459
Open Access | Times Cited: 11
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Reports (2024) Vol. 7, Iss. 4
Open Access | Times Cited: 4
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Reports (2024) Vol. 7, Iss. 4
Open Access | Times Cited: 4
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study
Masayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Journal of Gastroenterology (2024)
Open Access | Times Cited: 4
Masayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Journal of Gastroenterology (2024)
Open Access | Times Cited: 4
The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study
Takanori Suzuki, Kentaro Narita, Kentaro Matsuura, et al.
Oncology (2025), pp. 1-9
Closed Access
Takanori Suzuki, Kentaro Narita, Kentaro Matsuura, et al.
Oncology (2025), pp. 1-9
Closed Access
A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab–bevacizumab treatment
Takashi Hoshino, Atsushi Naganuma, Ai Furusawa, et al.
Clinical Journal of Gastroenterology (2022) Vol. 15, Iss. 4, pp. 776-783
Closed Access | Times Cited: 18
Takashi Hoshino, Atsushi Naganuma, Ai Furusawa, et al.
Clinical Journal of Gastroenterology (2022) Vol. 15, Iss. 4, pp. 776-783
Closed Access | Times Cited: 18
Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Hepatology International (2022) Vol. 17, Iss. 1, pp. 86-96
Closed Access | Times Cited: 17
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Hepatology International (2022) Vol. 17, Iss. 1, pp. 86-96
Closed Access | Times Cited: 17
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 2, pp. 233-245
Closed Access | Times Cited: 3
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 2, pp. 233-245
Closed Access | Times Cited: 3
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Hepatology Research (2024)
Open Access | Times Cited: 3
Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Hepatology Research (2024)
Open Access | Times Cited: 3
Tumor‐infiltrating CD8+ T‐cell numbers and serum C‐reactive protein levels as a prognostic biomarker in hepatocellular carcinoma patients receiving atezolizumab plus bevacizumab
Akifumi Kuwano, Masayoshi Yada, Masatake Tanaka, et al.
Hepatology Research (2025) Vol. 55, Iss. 4, pp. 600-610
Closed Access
Akifumi Kuwano, Masayoshi Yada, Masatake Tanaka, et al.
Hepatology Research (2025) Vol. 55, Iss. 4, pp. 600-610
Closed Access
